Who are we?
About us
Abmuno II builds on the legacy of Abmuno Therapeutics, which rapidly advanced a lead program by matching the right biology with the right engineered therapeutic modality. That deliberate, urgency-driven focus remains central to our philosophy.
At Abmuno II, we advance a new frontier: Degrader Antibody Conjugates (DACs). By combining antibody precision with protein degradation, we aim to deliver therapies that are more selective, more effective, and safer.
We pursue only the most consequential opportunities, applying deliberate focus to programs with the greatest potential to succeed while being highly selective in the partnerships we form. Grounded in proven expertise and propelled by the promise of DACs, Abmuno II is positioned to deliver the next generation of therapies.
Team and Advisors
Omar Duramad, PhD
CEO & Co-Founder
Bill Mallet, PhD
Biologics Drug Discovery
Scot Liu, PhD
Translational Biology & Co-Founder
Leonard G. Presta, PhD
Advisor
Joseph McCracken, DVM, MS
Advisor
Sarah Bodary, PhD
Advisor
Shirley Clayton, MBA
Advisor